Medical

FSD Pharma has received FDA permission to design and submit an application for a new trial using a synthetic cannabinoid-based drug in the treatment of COVID-19.

Philadelphia, Pennsylvania-based cannabis company FSD Pharma has been granted permission by the Food and Drug Administration to submit an Investigational New Drug Application for a clinical trial using a synthetic cannabinoid drug called ultramicronized palmitoylethanolamide (micro PEA) to treat COVID-19.

As it contends with the ongoing coronavirus pandemic, Missouri's health department published its first constitutionally required annual report to the governor on the fledgling medical marijuana program.

The Czech government has released details of new cultivation and export rules expected to be introduced in the country’s medical cannabis sector. The new rules will stem from a Bill aimed at reforming the Czech Republic’s Act on Addictive Substances.

Starting June 2, patients previously tied to one provider can purchase medical cannabis from any dispensary in the state.

Oklahoma's medical marijuana industry continues to break sales records.

Dispensaries remitted nearly $5.1 million via the state's 7% tax on cannabis, meaning customers spent approximately $73.8 million on medical marijuana in April, according to data released by state tax officials..

It's the fourth month in a row sales increased compared with the previous month, a trend that highlights a growing demand for the product more than a year after dispensaries first opened their doors.

Legislators passed a bill on Sunday that authorizes the recommendation of medical marijuana for additional conditions and allows any state-licensed physician to recommend medical marijuana.

The bill, HB 819 by Rep. Larry Bagley R-Stonewall, went before a House concurrence on Sunday where it passed 74 - 16. The amendments from the Senate were also concurred in.

Senate President Page Cortez then signed the bill, which now heads to Gov. John Bel Edwards to be signed into law.

Florida’s medical cannabis marketplace is based on the vertical integration of participating companies; this can be good for regulators and tax dollars, but very bad for patients and consumers.

A bill that would allow any condition to be treated with medical marijuana and any doctor in good standing to recommend it continued to build momentum in the Louisiana Legislature Wednesday with little resistance.

Members of the Senate Health and Welfare Committee approved House Bill 819 by Rep. Larry Bagley, R-Stonewall, to expand treatable conditions.

The bill has already secured full approval in the House and now heads to the full Senate for debate.

Most Canadian pediatricians are shying away from medical cannabis for patients, knowing that it can hurt the developing brain and that there isn’t much research to guide them.

But physicians say they are getting increasing requests for cannabis from parents, for a growing list of conditions.

Dr. Adam Rapoport, medical director of the pediatric palliative care team at the Hospital for Sick Children in Toronto, says, “This is mostly driven by parents, and doctors have fallen behind.”

Millions of people across the U.S. can legally buy pot at dispensaries — but scientists aren’t allowed to study it.

Early in Dr. Sue Sisley’s medical career, military veterans with post-traumatic stress disorder told her that smoking marijuana prevented nightmares and helped them sleep. Sisley, a primary care physician and psychiatrist in Scottsdale, Arizona, who has treated vets for two decades, said she was initially skeptical of her patients’ claims, but their families vouched that pot was helping with their symptoms.